IF YOU SUFFERED A LOSS ON YOUR MOONLAKE INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS. What Happened? On September 28, 2025, MoonLake Immunotherapeutics announced disappointing Phase 3 results for its only drug candidate, sonelokimab ("SLK†), revealing that SLK failed to match the efficacy of its competitor, Union Chimique Belge's bimekizumab-bkz ("BIMZELX†). The Company had repeatedly promoted SLK's nanobody structure as supe ...

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)?Did you purchase your shares between March 10, 2024 and September 29, 2025, inc ...

Accessibility StatementSkip Navigation SAN FRANCISCO, Oct. 30, 2025 /PRNewswire/ -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: MLTX) announced disastrous Phase 3 trial results for its only product candidate (sonelokimab, or "SLK"), its highly anticipated treatment for patients with skin disease (hidradenitis suppurativa or "HS"). On this announcement, MoonLake investors saw the price of their shares ...

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics. Investors have until December 15, 2025, to ask the Court to be app ...

Oct 28, 2025 12:03 PM Eastern Daylight Time Law Offices of Frank R. Cruz Encourages MoonLake Immunotherapeutics (MLTX) Shareholders to Inquire About Securities Fraud Class Action Share LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased MoonLake Immunotherapeutics ("MoonLake†or the "Company†) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the "Class Period†). M ...

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics. Investors have until December 15, 2025, to ask the Court to be app ...

SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- DiCello Levitt LLP announces that a class action lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX), along with certain individuals, alleging that they violated federal securities laws by issuing false and/or misleading statements concerning the Company’s business, operations, and prospects. The suit is brought on behalf of all those who purchased or otherwise acquired MoonLake common stock between March 10, 2024 through September 29, 2025, ...

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)?Did you purchase your shares between March 10, 2024 and September 29, 2025, inclusive?Did you lose money in your investment in MoonLake Immunotherapeutics?Do you want to discuss your rights? Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) investors of an upcomi ...

Accessibility StatementSkip Navigation PHILADELPHIA, Oct. 27, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period"). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, ...

Accessibility StatementSkip Navigation SAN DIEGO, Oct. 27, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Peters v. MoonLake Immunotherapeutics, No. 25-cv-08612, and pending in the Southern District of New York – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock and charges MoonLake as well as certain of MoonLake's top executives with violations of the Securities Exchange Act of 1934. http ...